Suvanza, Inc. provides topical treatment with Mycophin anti-Fungal Gel. The Company has successfully completed clinical trials, for such indications as Onychomycosis, Tinea Capitis and Tinea Corporis. Suvanza's delivery system uses less active ingredients, has reduced systemic uptake, and provides the opportunity to use multiple actives, which do not interact prior to application. The Company's Technology consists of three components: Active Ingredient, Macro Bead Technology and Protecting Gel Vehicle. The Active Ingredient uses physical chemical modulation in nano vesicle formulation, for a targeted penetration in skin, hair and nails diseases. The Suvanza Technology targets disease sites such as skin surface, hair and nails, filling a void in topical therapy in those areas.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | -- |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | -- |
| Free Float | -- |
| Market Capitalization | -- |
| Average Volume (Last 20 Days) | -- |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | -- |